Efficacy of Gefitinib Combined with 125I Radioactive Particles in the Treatment of Transplanted Lung Cancer Tumors in Nude Mice

Objective To investigate the efficacy of gefitinib combined with iodine-125 ( 125 I) radioactive particles in the treatment of transplanted tumors of the lung cancer cell line A549 in nude mice. Materials and Methods Twenty-four nude mice were inoculated with A549-luc human lung adenocarcinoma cells...

Full description

Saved in:
Bibliographic Details
Published inCardiovascular and interventional radiology Vol. 43; no. 9; pp. 1364 - 1370
Main Authors Li, Chaojie, Yao, Linyan, Gong, Ju, Pang, Haopeng, Shan, Qungang, Wang, Ziyin, Lu, Jian, Wang, Zhongmin
Format Journal Article
LanguageEnglish
Published New York Springer US 01.09.2020
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objective To investigate the efficacy of gefitinib combined with iodine-125 ( 125 I) radioactive particles in the treatment of transplanted tumors of the lung cancer cell line A549 in nude mice. Materials and Methods Twenty-four nude mice were inoculated with A549-luc human lung adenocarcinoma cells stably expressing luciferase. The tumor size was approximately 8–10 mm after 20 days. The mice were randomly divided into four groups: a control group ( n  = 6), an 125 I particles group ( n  = 6), a gefitinib group ( n  = 6) and a gefitinib combined 125 I particles implantation group ( n  = 6). Tumor growth was observed, and changes in tumor size were continuously measured. Bioluminescence imaging was used to detect the bioluminescence activity of human lung adenocarcinoma A549-luc cells containing the luciferase reporter gene in vivo. After 35 days, the nude mice were sacrificed, and a tumor growth curve was drawn. Results Before treatment, the tumor volumes of the four groups were not significantly different. The tumor volume difference was statistically significant in the four groups (control group, 125 I radioactive particles, gefitinib group and combined drug group) at 5 weeks after treatment ( F  = 10.305, P  < 0.05). The tumor size in the gefitinib combined with 125 I particles group was significantly smaller than that in the gefitinib, 125 I particles and control groups and significantly smaller than that before treatment. There was no significant difference in the bioluminescence signal intensity between the four groups before treatment. The numbers of biofluorescence photons difference were statistically significant in the four groups ( F  = 28.975, P  < 0.05). The bioluminescence signal intensity in the gefitinib combined with 125 I particles group was significantly lower than that in the 125 I particles, gefitinib and control groups and significantly lower than that before treatment. Conclusion Gefitinib combined with 125 I radioactive particles brachytherapy can significantly inhibit tumor growth.
AbstractList ObjectiveTo investigate the efficacy of gefitinib combined with iodine-125 (125I) radioactive particles in the treatment of transplanted tumors of the lung cancer cell line A549 in nude mice.Materials and MethodsTwenty-four nude mice were inoculated with A549-luc human lung adenocarcinoma cells stably expressing luciferase. The tumor size was approximately 8–10 mm after 20 days. The mice were randomly divided into four groups: a control group (n = 6), an 125I particles group (n = 6), a gefitinib group (n = 6) and a gefitinib combined 125I particles implantation group (n = 6). Tumor growth was observed, and changes in tumor size were continuously measured. Bioluminescence imaging was used to detect the bioluminescence activity of human lung adenocarcinoma A549-luc cells containing the luciferase reporter gene in vivo. After 35 days, the nude mice were sacrificed, and a tumor growth curve was drawn.ResultsBefore treatment, the tumor volumes of the four groups were not significantly different. The tumor volume difference was statistically significant in the four groups (control group, 125I radioactive particles, gefitinib group and combined drug group) at 5 weeks after treatment (F = 10.305, P < 0.05). The tumor size in the gefitinib combined with 125I particles group was significantly smaller than that in the gefitinib, 125I particles and control groups and significantly smaller than that before treatment. There was no significant difference in the bioluminescence signal intensity between the four groups before treatment. The numbers of biofluorescence photons difference were statistically significant in the four groups (F = 28.975, P < 0.05). The bioluminescence signal intensity in the gefitinib combined with 125I particles group was significantly lower than that in the 125I particles, gefitinib and control groups and significantly lower than that before treatment.ConclusionGefitinib combined with 125I radioactive particles brachytherapy can significantly inhibit tumor growth.
Objective To investigate the efficacy of gefitinib combined with iodine-125 ( 125 I) radioactive particles in the treatment of transplanted tumors of the lung cancer cell line A549 in nude mice. Materials and Methods Twenty-four nude mice were inoculated with A549-luc human lung adenocarcinoma cells stably expressing luciferase. The tumor size was approximately 8–10 mm after 20 days. The mice were randomly divided into four groups: a control group ( n  = 6), an 125 I particles group ( n  = 6), a gefitinib group ( n  = 6) and a gefitinib combined 125 I particles implantation group ( n  = 6). Tumor growth was observed, and changes in tumor size were continuously measured. Bioluminescence imaging was used to detect the bioluminescence activity of human lung adenocarcinoma A549-luc cells containing the luciferase reporter gene in vivo. After 35 days, the nude mice were sacrificed, and a tumor growth curve was drawn. Results Before treatment, the tumor volumes of the four groups were not significantly different. The tumor volume difference was statistically significant in the four groups (control group, 125 I radioactive particles, gefitinib group and combined drug group) at 5 weeks after treatment ( F  = 10.305, P  < 0.05). The tumor size in the gefitinib combined with 125 I particles group was significantly smaller than that in the gefitinib, 125 I particles and control groups and significantly smaller than that before treatment. There was no significant difference in the bioluminescence signal intensity between the four groups before treatment. The numbers of biofluorescence photons difference were statistically significant in the four groups ( F  = 28.975, P  < 0.05). The bioluminescence signal intensity in the gefitinib combined with 125 I particles group was significantly lower than that in the 125 I particles, gefitinib and control groups and significantly lower than that before treatment. Conclusion Gefitinib combined with 125 I radioactive particles brachytherapy can significantly inhibit tumor growth.
Author Li, Chaojie
Shan, Qungang
Lu, Jian
Pang, Haopeng
Wang, Ziyin
Yao, Linyan
Wang, Zhongmin
Gong, Ju
Author_xml – sequence: 1
  givenname: Chaojie
  surname: Li
  fullname: Li, Chaojie
  organization: Department of Radiology, Ruijin Hospital/Luwan Branch, Shanghai Jiao Tong University School of Medicine
– sequence: 2
  givenname: Linyan
  surname: Yao
  fullname: Yao, Linyan
  organization: Department of Radiology, Ruijin Hospital/Luwan Branch, Shanghai Jiao Tong University School of Medicine
– sequence: 3
  givenname: Ju
  surname: Gong
  fullname: Gong, Ju
  organization: Department of Radiology, Ruijin Hospital/Luwan Branch, Shanghai Jiao Tong University School of Medicine
– sequence: 4
  givenname: Haopeng
  surname: Pang
  fullname: Pang, Haopeng
  organization: Department of Radiology, Ruijin Hospital/Luwan Branch, Shanghai Jiao Tong University School of Medicine
– sequence: 5
  givenname: Qungang
  surname: Shan
  fullname: Shan, Qungang
  organization: Department of Radiology, Ruijin Hospital/Luwan Branch, Shanghai Jiao Tong University School of Medicine
– sequence: 6
  givenname: Ziyin
  surname: Wang
  fullname: Wang, Ziyin
  organization: Department of Radiology, Ruijin Hospital/Luwan Branch, Shanghai Jiao Tong University School of Medicine
– sequence: 7
  givenname: Jian
  surname: Lu
  fullname: Lu, Jian
  email: 1355457662@qq.com
  organization: Department of Radiology, Ruijin Hospital/Luwan Branch, Shanghai Jiao Tong University School of Medicine
– sequence: 8
  givenname: Zhongmin
  surname: Wang
  fullname: Wang, Zhongmin
  email: wzm0722@hotmail.com
  organization: Department of Radiology, Ruijin Hospital/Luwan Branch, Shanghai Jiao Tong University School of Medicine
BookMark eNp9kE1LAzEQhoMo2Fb_gKeA59Uku9ntHmWptVA_kAreQjaZtCndbE2ySk_-dbet4M3DMJf3eYd5hujUtQ4QuqLkhhJS3AZCWEESwvbDOUnoCRrQLGUJGefvp2hAaJEllHN6joYhrAmhfMz4AH1PjLFKqh1uDZ6CsdE6W-OqbWrrQOMvG1eYMj7Dr1LbVqpoPwG_SB-t2kDA1uG4ArzwIGMDLu5rFl66sN1IF_uCeeeWuJJOgceLrmn9gXnqNOBHq-ACnRm5CXD5u0fo7X6yqB6S-fN0Vt3NE8WyMiacacLTMuOayFqaHJRkqsw1VRkHbmitTZlKarK0f6so8ppoaXSpGU1VqdIiHaHrY-_Wtx8dhCjWbeddf1KwHspZkVPep9gxpXwbggcjtt420u8EJWIvWhxFi160OIgWtIfSIxT6sFuC_6v-h_oBolOCsQ
CitedBy_id crossref_primary_10_1155_2021_2472444
crossref_primary_10_1155_2022_7376844
crossref_primary_10_3892_etm_2021_10873
Cites_doi 10.1200/JCO.2005.09.985
10.1016/j.critrevonc.2013.08.003
10.7314/APJCP.2013.14.10.5725
10.1038/nrc.2017.84
10.5966/sctm.2013-0132
10.1136/pmj.78.924.584
10.3390/ijms16034918
10.1007/s00432-014-1655-x
10.1093/jjco/hym089
10.1111/jgh.13261
10.1158/1078-0432.CCR-06-0627
10.1016/j.clinthera.2013.08.007
10.1016/j.brachy.2018.03.002
10.7314/APJCP.2015.16.9.4003
10.2217/fon.13.56
10.1117/1.NPh.3.2.025001
10.1158/1078-0432.CCR-09-1149
10.3322/caac.21349
10.3322/caac.21551
10.1016/j.lungcan.2015.07.004
10.1016/j.biomaterials.2013.07.100
ContentType Journal Article
Copyright Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2020
Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2020.
Copyright_xml – notice: Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2020
– notice: Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2020.
DBID AAYXX
CITATION
3V.
7RV
7TO
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
KB0
M0S
M1P
NAPCQ
PQEST
PQQKQ
PQUKI
PRINS
DOI 10.1007/s00270-020-02550-1
DatabaseName CrossRef
ProQuest Central (Corporate)
ProQuest Nursing & Allied Health Database
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Nursing & Allied Health Premium
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
DatabaseTitle CrossRef
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
AIDS and Cancer Research Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
DatabaseTitleList Oncogenes and Growth Factors Abstracts

Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-086X
EndPage 1370
ExternalDocumentID 10_1007_s00270_020_02550_1
GrantInformation_xml – fundername: Natural Science Foundation of Shanghai
  grantid: 19ZR1432600
  funderid: http://dx.doi.org/10.13039/100007219
– fundername: Postdoctoral Research Foundation of China
  grantid: 2015T80489
  funderid: http://dx.doi.org/10.13039/501100010031
– fundername: Shanghai Key Specialty Construction Project
  grantid: ZK2019A02
– fundername: Shanghai Municipal Key Clinical Specialty
  grantid: shslczdzk07002; shslczdzk06002
– fundername: Shanghai Municipal Health Bureau
  grantid: 201640015
  funderid: http://dx.doi.org/10.13039/501100007279
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
04C
06C
06D
0R~
0VY
1N0
1SB
2.D
203
28-
29B
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
6PF
78A
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AABYN
AAFGU
AAHNG
AAIAL
AAJKR
AAKSU
AANXM
AANZL
AAPBV
AARHV
AARTL
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYFA
AAYIU
AAYQN
AAYTO
ABBBX
ABBXA
ABDZT
ABECU
ABFGW
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKAS
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABOCM
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACBMV
ACBRV
ACBXY
ACBYP
ACGFS
ACHSB
ACHVE
ACHXU
ACIGE
ACIPQ
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPRK
ACTTH
ACUDM
ACVWB
ACWMK
ADBBV
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADMDM
ADOXG
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEEQQ
AEFIE
AEFTE
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AENEX
AEOHA
AEPYU
AESKC
AESTI
AETLH
AEVLU
AEVTX
AEXYK
AFAFS
AFEXP
AFJLC
AFKRA
AFLOW
AFNRJ
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGBP
AGGDS
AGJBK
AGKHE
AGMZJ
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AIMYW
AITGF
AJBLW
AJDOV
AJRNO
AJZVZ
AKMHD
AKQUC
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKEYQ
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UNUBA
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
WOW
YLTOR
Z45
Z7U
Z7V
Z7X
Z7Y
Z82
Z83
Z87
Z8O
Z8P
Z8S
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
~EX
AACDK
AAEOY
AAJBT
AASML
AAYXX
AAYZH
ABAKF
ABQSL
ACAOD
ACDTI
ACZOJ
AEFQL
AEMSY
AFBBN
AGQEE
AGRTI
AIGIU
AJOOF
ALIPV
CITATION
H13
7TO
7XB
8FK
H94
K9.
PQEST
PQUKI
PRINS
ID FETCH-LOGICAL-c249t-52d053945d0abaf6eca2c96d1c45e5f1bdf93a1f43582776b0dafd9d213c9c373
IEDL.DBID 7X7
ISSN 0174-1551
IngestDate Thu Oct 10 22:46:11 EDT 2024
Fri Dec 06 02:12:13 EST 2024
Sat Dec 16 12:03:29 EST 2023
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords I radioactive particles
fluorine-fluorinedeoxyglucose
Lung adenocarcinoma
Biofluorescence imaging
Gefitinib
F-FDG
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c249t-52d053945d0abaf6eca2c96d1c45e5f1bdf93a1f43582776b0dafd9d213c9c373
PQID 2435627615
PQPubID 54058
PageCount 7
ParticipantIDs proquest_journals_2435627615
crossref_primary_10_1007_s00270_020_02550_1
springer_journals_10_1007_s00270_020_02550_1
PublicationCentury 2000
PublicationDate 2020-09-01
PublicationDateYYYYMMDD 2020-09-01
PublicationDate_xml – month: 09
  year: 2020
  text: 2020-09-01
  day: 01
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: Vienna
PublicationTitle Cardiovascular and interventional radiology
PublicationTitleAbbrev Cardiovasc Intervent Radiol
PublicationYear 2020
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References Kim, Kim, Cho, Pyo, Shim, Chang, Park, Suh, Park, Kim (CR9) 2002; 95
Kim, Woo, Jeong, Ryu, Jang, Jeun (CR22) 2014; 3
Yewale, Baradia, Vhora, Patil, Misra (CR17) 2013; 34
Luo, Liu, Ye, Fu, Lu, Suleiman, Liao, Xiao (CR15) 2016; 31
Bronte, Rolfo, Giovannetti, Cicero, Pauwels, Passiglia, Castiglia, Rizzo, Vullo, Fiorentino, Van Meerbeeck, Russo (CR13) 2014; 89
Goffin, Zbuk (CR18) 2013; 35
Kao, Lin, Yang (CR19) 2013; 9
Rotow, Bivona (CR14) 2017; 17
He, Li, Liu, Zhang (CR4) 2018; 17
Gotoh, Takiuchi, Kawabe, Ohta, Kii, Kuwakado, Katsu (CR10) 2007; 37
Li, Sun, Liu (CR16) 2015; 16
Colquhoun, Mellon (CR8) 2002; 78
Akhtar-Danesh, Finley (CR3) 2015; 90
Janne, Engelman, Johnson (CR7) 2005; 23
Li, Yang, Mei, Chen, Zhang, Sun, Zhou, Zhou, Xie (CR6) 2013; 14
Rosell, Taron, Reguart, Isla, Moran (CR12) 2006; 12
Miller, Siegel, Lin, Mariotto, Kramer, Rowland, Stein, Alteri, Jemal (CR1) 2016; 66
Siegel, Miller, Jemal (CR2) 2019; 69
Noordhuis, Eijsink, Ten, Roossink, Hollema, Arts, Pras, Maduro, Reyners, de Bock, Wisman, Schuuring, van der Zee (CR11) 2009; 15
Weber, Haberkorn, Mier (CR20) 2015; 16
Zhang, Lu, Peng, Zhang, Yang, Liu, Singh, Yang, Zhang, Gao (CR5) 2014; 140
Tung, Berglund, Gutekunst, Hochgeschwender, Gross (CR21) 2016; 3
N Akhtar-Danesh (2550_CR3) 2015; 90
KD Miller (2550_CR1) 2016; 66
SM Kim (2550_CR22) 2014; 3
M Gotoh (2550_CR10) 2007; 37
R Rosell (2550_CR12) 2006; 12
MG Noordhuis (2550_CR11) 2009; 15
HF Kao (2550_CR19) 2013; 9
JR Goffin (2550_CR18) 2013; 35
G Bronte (2550_CR13) 2014; 89
J Weber (2550_CR20) 2015; 16
JK Tung (2550_CR21) 2016; 3
J Li (2550_CR6) 2013; 14
AJ Colquhoun (2550_CR8) 2002; 78
YJ Luo (2550_CR15) 2016; 31
PA Janne (2550_CR7) 2005; 23
Y He (2550_CR4) 2018; 17
RL Siegel (2550_CR2) 2019; 69
C Yewale (2550_CR17) 2013; 34
T Zhang (2550_CR5) 2014; 140
YB Kim (2550_CR9) 2002; 95
J Rotow (2550_CR14) 2017; 17
JR Li (2550_CR16) 2015; 16
References_xml – volume: 23
  start-page: 3227
  issue: 14
  year: 2005
  end-page: 3234
  ident: CR7
  article-title: Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.09.985
  contributor:
    fullname: Johnson
– volume: 95
  start-page: 531
  issue: 3
  year: 2002
  end-page: 539
  ident: CR9
  article-title: Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy
  publication-title: Cancer-Am. Cancer Soc.
  contributor:
    fullname: Kim
– volume: 89
  start-page: 300
  issue: 2
  year: 2014
  end-page: 313
  ident: CR13
  article-title: Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2013.08.003
  contributor:
    fullname: Russo
– volume: 14
  start-page: 5725
  issue: 10
  year: 2013
  end-page: 5730
  ident: CR6
  article-title: Involvement of cdc25c in cell cycle alteration of a radioresistant lung cancer cell line established with fractionated ionizing radiation
  publication-title: Asian Pac J Cancer Prev
  doi: 10.7314/APJCP.2013.14.10.5725
  contributor:
    fullname: Xie
– volume: 17
  start-page: 637
  issue: 11
  year: 2017
  end-page: 658
  ident: CR14
  article-title: Understanding and targeting resistance mechanisms in NSCLC
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2017.84
  contributor:
    fullname: Bivona
– volume: 3
  start-page: 172
  issue: 2
  year: 2014
  end-page: 182
  ident: CR22
  article-title: Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma
  publication-title: Stem Cells Transl Med
  doi: 10.5966/sctm.2013-0132
  contributor:
    fullname: Jeun
– volume: 78
  start-page: 584
  issue: 924
  year: 2002
  end-page: 589
  ident: CR8
  article-title: Epidermal growth factor receptor and bladder cancer
  publication-title: Postgrad Med J
  doi: 10.1136/pmj.78.924.584
  contributor:
    fullname: Mellon
– volume: 16
  start-page: 4918
  issue: 3
  year: 2015
  end-page: 4946
  ident: CR20
  article-title: Cancer stratification by molecular imaging
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms16034918
  contributor:
    fullname: Mier
– volume: 140
  start-page: 1383
  issue: 8
  year: 2014
  end-page: 1390
  ident: CR5
  article-title: CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-014-1655-x
  contributor:
    fullname: Gao
– volume: 37
  start-page: 652
  issue: 9
  year: 2007
  end-page: 657
  ident: CR10
  article-title: Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma
  publication-title: Jpn J Clin Oncol
  doi: 10.1093/jjco/hym089
  contributor:
    fullname: Katsu
– volume: 31
  start-page: 1076
  issue: 6
  year: 2016
  end-page: 1084
  ident: CR15
  article-title: Safety and efficacy of intraoperative iodine-125 seed implantation brachytherapy for rectal cancer patients: a retrospective clinical research
  publication-title: J Gastroenterol Hepatol
  doi: 10.1111/jgh.13261
  contributor:
    fullname: Xiao
– volume: 12
  start-page: 7222
  issue: 24
  year: 2006
  end-page: 7231
  ident: CR12
  article-title: Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-0627
  contributor:
    fullname: Moran
– volume: 35
  start-page: 1282
  issue: 9
  year: 2013
  end-page: 1303
  ident: CR18
  article-title: Epidermal growth factor receptor: pathway, therapies, and pipeline
  publication-title: Clin Ther
  doi: 10.1016/j.clinthera.2013.08.007
  contributor:
    fullname: Zbuk
– volume: 17
  start-page: 696
  issue: 4
  year: 2018
  end-page: 701
  ident: CR4
  article-title: Iodine-125 seed brachytherapy inhibits non-small cell lung cancer by suppressing epithelial-mesenchymal transition
  publication-title: Brachytherapy
  doi: 10.1016/j.brachy.2018.03.002
  contributor:
    fullname: Zhang
– volume: 16
  start-page: 4003
  issue: 9
  year: 2015
  end-page: 4006
  ident: CR16
  article-title: Radioactive seed implantation and lobaplatin chemotherapy are safe and effective in treating patients with advanced lung cancer
  publication-title: Asian Pac J Cancer Prev
  doi: 10.7314/APJCP.2015.16.9.4003
  contributor:
    fullname: Liu
– volume: 9
  start-page: 991
  issue: 7
  year: 2013
  end-page: 1003
  ident: CR19
  article-title: EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
  publication-title: Future Oncol
  doi: 10.2217/fon.13.56
  contributor:
    fullname: Yang
– volume: 3
  start-page: 25001
  issue: 2
  year: 2016
  ident: CR21
  article-title: Bioluminescence imaging in live cells and animals
  publication-title: Neurophotonics
  doi: 10.1117/1.NPh.3.2.025001
  contributor:
    fullname: Gross
– volume: 15
  start-page: 7389
  issue: 23
  year: 2009
  end-page: 7397
  ident: CR11
  article-title: Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-1149
  contributor:
    fullname: van der Zee
– volume: 66
  start-page: 271
  issue: 4
  year: 2016
  end-page: 289
  ident: CR1
  article-title: Cancer treatment and survivorship statistics, 2016
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21349
  contributor:
    fullname: Jemal
– volume: 69
  start-page: 7
  issue: 1
  year: 2019
  end-page: 34
  ident: CR2
  article-title: Cancer statistics, 2019
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21551
  contributor:
    fullname: Jemal
– volume: 90
  start-page: 8
  issue: 1
  year: 2015
  end-page: 14
  ident: CR3
  article-title: Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: a population-based study
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2015.07.004
  contributor:
    fullname: Finley
– volume: 34
  start-page: 8690
  issue: 34
  year: 2013
  end-page: 8707
  ident: CR17
  article-title: Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2013.07.100
  contributor:
    fullname: Misra
– volume: 17
  start-page: 696
  issue: 4
  year: 2018
  ident: 2550_CR4
  publication-title: Brachytherapy
  doi: 10.1016/j.brachy.2018.03.002
  contributor:
    fullname: Y He
– volume: 23
  start-page: 3227
  issue: 14
  year: 2005
  ident: 2550_CR7
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.09.985
  contributor:
    fullname: PA Janne
– volume: 89
  start-page: 300
  issue: 2
  year: 2014
  ident: 2550_CR13
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2013.08.003
  contributor:
    fullname: G Bronte
– volume: 35
  start-page: 1282
  issue: 9
  year: 2013
  ident: 2550_CR18
  publication-title: Clin Ther
  doi: 10.1016/j.clinthera.2013.08.007
  contributor:
    fullname: JR Goffin
– volume: 15
  start-page: 7389
  issue: 23
  year: 2009
  ident: 2550_CR11
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-1149
  contributor:
    fullname: MG Noordhuis
– volume: 16
  start-page: 4918
  issue: 3
  year: 2015
  ident: 2550_CR20
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms16034918
  contributor:
    fullname: J Weber
– volume: 37
  start-page: 652
  issue: 9
  year: 2007
  ident: 2550_CR10
  publication-title: Jpn J Clin Oncol
  doi: 10.1093/jjco/hym089
  contributor:
    fullname: M Gotoh
– volume: 12
  start-page: 7222
  issue: 24
  year: 2006
  ident: 2550_CR12
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-0627
  contributor:
    fullname: R Rosell
– volume: 3
  start-page: 25001
  issue: 2
  year: 2016
  ident: 2550_CR21
  publication-title: Neurophotonics
  doi: 10.1117/1.NPh.3.2.025001
  contributor:
    fullname: JK Tung
– volume: 78
  start-page: 584
  issue: 924
  year: 2002
  ident: 2550_CR8
  publication-title: Postgrad Med J
  doi: 10.1136/pmj.78.924.584
  contributor:
    fullname: AJ Colquhoun
– volume: 95
  start-page: 531
  issue: 3
  year: 2002
  ident: 2550_CR9
  publication-title: Cancer-Am. Cancer Soc.
  contributor:
    fullname: YB Kim
– volume: 9
  start-page: 991
  issue: 7
  year: 2013
  ident: 2550_CR19
  publication-title: Future Oncol
  doi: 10.2217/fon.13.56
  contributor:
    fullname: HF Kao
– volume: 69
  start-page: 7
  issue: 1
  year: 2019
  ident: 2550_CR2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21551
  contributor:
    fullname: RL Siegel
– volume: 66
  start-page: 271
  issue: 4
  year: 2016
  ident: 2550_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21349
  contributor:
    fullname: KD Miller
– volume: 140
  start-page: 1383
  issue: 8
  year: 2014
  ident: 2550_CR5
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-014-1655-x
  contributor:
    fullname: T Zhang
– volume: 17
  start-page: 637
  issue: 11
  year: 2017
  ident: 2550_CR14
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2017.84
  contributor:
    fullname: J Rotow
– volume: 3
  start-page: 172
  issue: 2
  year: 2014
  ident: 2550_CR22
  publication-title: Stem Cells Transl Med
  doi: 10.5966/sctm.2013-0132
  contributor:
    fullname: SM Kim
– volume: 14
  start-page: 5725
  issue: 10
  year: 2013
  ident: 2550_CR6
  publication-title: Asian Pac J Cancer Prev
  doi: 10.7314/APJCP.2013.14.10.5725
  contributor:
    fullname: J Li
– volume: 31
  start-page: 1076
  issue: 6
  year: 2016
  ident: 2550_CR15
  publication-title: J Gastroenterol Hepatol
  doi: 10.1111/jgh.13261
  contributor:
    fullname: YJ Luo
– volume: 34
  start-page: 8690
  issue: 34
  year: 2013
  ident: 2550_CR17
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2013.07.100
  contributor:
    fullname: C Yewale
– volume: 16
  start-page: 4003
  issue: 9
  year: 2015
  ident: 2550_CR16
  publication-title: Asian Pac J Cancer Prev
  doi: 10.7314/APJCP.2015.16.9.4003
  contributor:
    fullname: JR Li
– volume: 90
  start-page: 8
  issue: 1
  year: 2015
  ident: 2550_CR3
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2015.07.004
  contributor:
    fullname: N Akhtar-Danesh
SSID ssj0015825
Score 2.3326101
Snippet Objective To investigate the efficacy of gefitinib combined with iodine-125 ( 125 I) radioactive particles in the treatment of transplanted tumors of the lung...
ObjectiveTo investigate the efficacy of gefitinib combined with iodine-125 (125I) radioactive particles in the treatment of transplanted tumors of the lung...
SourceID proquest
crossref
springer
SourceType Aggregation Database
Publisher
StartPage 1364
SubjectTerms Adenocarcinoma
Bioluminescence
Brachytherapy
Cardiology
Gefitinib
Imaging
Implantation
Inhibitor drugs
Interventional Oncology
Iodine
Iodine 125
Iodine isotopes
Iodine radioisotopes
Laboratory Investigation
Lung cancer
Lung transplantation
Medicine
Medicine & Public Health
Nuclear Medicine
Photons
Radiation therapy
Radiology
Reporter gene
Statistical analysis
Statistical significance
Surgical implants
Targeted cancer therapy
Tempering
Tumors
Ultrasound
SummonAdditionalLinks – databaseName: SpringerLINK - Czech Republic Consortium
  dbid: AGYKE
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1JS8NAFB6kBfHiLlarzMGbpiSZJNMcS-ni0iLSQj2FWSGoqdTkoBf_um-ytLgdCrkleSTvvXnzfXlLELoQHtXMpRyQGwOCogWxQptoyxXgUTZrK8JNc_JoHAyn3s3Mn636uPNi9yojmQfqZa-bIVC2ZdiOgcG2BZSnDnuPWY31zuDxtrdMHvhtt6hcpJ5lEEHZK_O3lO_70Qpk_siL5ttNfwdNqqadosrkqZWlvCU-fs9wXOdNdtF2CT9xp_CXPbShkn20OSoT7Afos2dGSjDxjucaD5SO0ziJOYaoAQxaSWw-22JAK9f4gcl4zvJoie-r8jocJxgQJZ5U5etGTDE__dmYUOI7CC64a1xtgSfZy3yR3zPOpMIjiFmHaNrvTbpDq_xHgyWAuKXAYyUs49Dzpc0404ESzBVhIB3h-crXDpc6JMzRnunIpTTgtmRahtJ1iAgFoeQI1ZJ5oo4RJhDrfBAgqWgDjeK8bSufEzgCznxKGuiyslT0WoziiJZDl3OdRqDTKNdp5DRQszJmVC7Lt8iFxwhcCiiuga4q46xO_y_tZL3LT9GWm9vX1KI1US1dZOoMwEvKz0tn_QLzE-NX
  priority: 102
  providerName: Springer Nature
Title Efficacy of Gefitinib Combined with 125I Radioactive Particles in the Treatment of Transplanted Lung Cancer Tumors in Nude Mice
URI https://link.springer.com/article/10.1007/s00270-020-02550-1
https://www.proquest.com/docview/2435627615
Volume 43
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LSwMxEA4-QLyIT6wvcvCmi7vJZtM9SSutzxaRFuppyRMWdLfW9uDJv-4k3bUoKCzkEHYOmcnM9yUzE4ROVcytIFwCchNAUKyiQRpSGxAFFhWKpqHSFSf3-snNML4bsVF14PZepVXWPtE7al0qd0Z-QSCuJwRIN7scvwXu1Sh3u1o9obGMViMCoRzsmY--CVfEmmSewsjjwEGDqmjGl845PhYGjjw5VB0G0c_AtECbvy5IfdzpbqKNCjDi1lzDW2jJFNtorVddie-gz45rAiHUBy4tvjY2n-ZFLjHsc-C8RmN30IoBX9ziJ6HzUnj_hh_rhDicFxgwIB7UCedOzLzj-YtbdI0fwB3gK2ccEzyYvZYT_09_pg3ugZfZRcNuZ3B1E1SvKgQKqNYUmKeGjZfGTIdCCpsYJYhKEx2pmBlmI6ltSkVkY1dDy3kiQy2sTjWJqEoV5XQPrRRlYfYRpuCdGAjQXDWB-EjZDA2TFL5ECsZpA53VS5qN580zsu82yV4BGSgg8wrIogY6qlc9qzbSe7ZQewOd15pYTP8t7eB_aYdonXjlu2yxI7QynczMMcCLqTzxNnSCVlvddrvvxuvn-w6M7U7_8Qlmh6T1BbmX0C4
link.rule.ids 314,780,784,12056,21388,27924,27925,31719,33744,41081,41523,42150,42592,43310,43805,52111,52234,73745,74302
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB60gnoRn1itugdvGkyy2aQ5iZZq1baIVPAW9gkBTbS2B0_-dWfTjUVBIbclc9h57PftPBbgWEaJ4WEiELlxJChGUi_1qfFCiRbl87amwjYnD4Zx7zG6fWJP7sLt3ZVV1jGxCtSqlPaO_CzEcz0OkXSz89c3z74aZbOr7gmNRViyk9NZA5Yuu8P7h-88AmuHsyLGJPIsOHBtM1XznGVkvmfpk8XVvhf8PJrmePNXirQ6ea7WYc1BRnIx0_EGLOhiE5YHLim-BZ9dOwaCyw9SGnKtTT7Ji1wQ9HRkvVoRe9VKEGHckAeu8pJXEY7c1yVxJC8IokAyqkvOrZjZzPNnu-2K9DEgkI41jzEZTV_KcfXPcKo0GWCc2YbHq-6o0_PcuwqeRLI1Qe6p0PXSiCmfC25iLXko01gFMmKamUAok1IemMh20SZJLHzFjUpVGFCZSprQHWgUZaF3gVCMTwwFqES2kfoI0fY1ExS_WHCW0Cac1Fuavc7GZ2Tfg5IrBWSogKxSQBY0oVXveuZc6T2bK74Jp7Um5st_S9v7X9oRrPRGg37Wvxne7cNqWBmCrR1rQWMynuoDBBsTcegs6gveUM7x
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9tAEB61iYR6QS0PNUDbPXADK_au145PqKUJoZAoQomUm7VPyRLYEJIDJ_46s846EZVaybeV57AzO_N9O48FOFVxagVNJSI3gQTFKhZkIbMBVWhRoegZJl1z8micDGfxnzmf-_qnZ19W2fjE2lHrSrk78i7FuJ5QJN28a31ZxOT34OLxKXAvSLlMq39O4yO0MSqGtAXtX_3x5G6TU-A9ui5oTOPAAQXfQlM30jl2FgaOSjmMHQbR-zC1xZ5_pUvrKDT4DLsePpKfa31_gQ-m3IOdkU-Q78Nr342EEOqFVJZcGVssi7KQBE89MmCjibt2JYg2rsmd0EUlam9HJk15HClKgoiQTJvycydmPf_83qlAk1t0DuTSmcqCTFcP1aL-Z7zShozQ5xzAbNCfXg4D_8ZCoJB4LZGHajyGWcx1KKSwiVGCqizRkYq54TaS2mZMRDZ2HbVpmshQC6szTSOmMsVSdgitsirNVyAMfRVHATpVPaRBUvZCwyXDL5GCp6wDZ82W5o_rURr5ZmhyrYAcFZDXCsijDpw0u577Y_Wcb42gA-eNJrbL_5Z29H9pP2AHjSm_vR7fHMMnWtuBKyM7gdZysTLfEHcs5XdvUG-VJNMe
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+Gefitinib+Combined+with+125I+Radioactive+Particles+in+the+Treatment+of+Transplanted+Lung+Cancer+Tumors+in+Nude+Mice&rft.jtitle=Cardiovascular+and+interventional+radiology&rft.au=Li%2C+Chaojie&rft.au=Yao%2C+Linyan&rft.au=Gong%2C+Ju&rft.au=Pang%2C+Haopeng&rft.date=2020-09-01&rft.issn=0174-1551&rft.eissn=1432-086X&rft.volume=43&rft.issue=9&rft.spage=1364&rft.epage=1370&rft_id=info:doi/10.1007%2Fs00270-020-02550-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00270_020_02550_1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0174-1551&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0174-1551&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0174-1551&client=summon